Modality
Gene Therapy
MOA
STINGag
Target
FGFR
Pathway
NF-κB
CSUMMEndometrial Ca
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
Jan 2024
→ Mar 2029
Phase 2Current
NCT04184483
2,007 pts·Endometrial Ca
2024-01→2029-03·Terminated
2,007 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-243.0y awayPh2 Data· Endometrial Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Termina…
Catalysts
Ph2 Data
2029-03-24 · 3.0y away
Endometrial Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04184483 | Phase 2 | Endometrial Ca | Terminated | 2007 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-5389 | Roche | Preclinical | RET | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |